Last Posted: Sep 13, 2019
- Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer
DJ Pinato et al, JAMA Oncology, September 12, 2019 - How Immunotherapy Might Be Used to Treat Heart Failure- Modified immune cells may be trained not just to attack cancer, but any cells in the body that cause disease
G Kolata, NY Times, September 11, 2019 - Noninvasive Detection of Microsatellite Instability and High Tumor Mutation Burden in Cancer Patients Treated with PD-1 Blockade.
Georgiadis Andrew et al. Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Sep - Clinical lessons learned from the first leg of the CAR T cell journey
RJ Majzner et al, Nature Medicine, September 10, 2019 - Opportunities in Cancer Research: The Immune System and Microbiome
NCI 2021 annual plan, 2019 - Clinical Validation of PBRM1 Alterations as a Marker of Immune Checkpoint Inhibitor Response in Renal Cell Carcinoma.
Braun David A et al. JAMA oncology 2019 Sep - Association of Germline Variants in Natural Killer Cells With Tumor Immune Microenvironment Subtypes, Tumor-Infiltrating Lymphocytes, Immunotherapy Response, Clinical Outcomes, and Cancer Risk.
Xu Xue et al. JAMA network open 2019 Sep (9) e199292 - Potential impact of immunotherapy agents on cognitive function in cancer patients
F Joly et al, JNCI, August 2019 - Clinical utility of a protein-based oncopanel in patients with end-stage head and neck cancer.
Doescher Johannes et al. Immunotherapy 2019 Aug - Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR
S Ghorashian et al, Nature Medicine, September 2, 2019
.png)
No hay comentarios:
Publicar un comentario